GLGS - Scimitar is initiating a “BUY’ of GlycoGenesys, Inc. (GLGS: NASDAQ). We project a FY05 target price of $2.25 for GLGS’s stock. If collaboration is consummated by the end of 2005 with a major pharmaceutical or biotechnology company to develop and commercialize GLGS’s GCS- 100 compounds, then our FY06 target price would be upgraded to $3.50 – 4.00.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.